Hirano, Shin-Ichi, Ichikawa, Yusuke, Sato, Bunpei et al. · Frontiers in neurology · 2022 · DOI
This review examines whether molecular hydrogen (H₂) gas might help treat ME/CFS by fixing problems in the energy-producing parts of cells. The researchers looked at existing studies showing that H₂ can reduce harmful molecules called free radicals and improve fatigue in animals and healthy people. While the idea is promising, the authors emphasize that more human studies are needed before H₂ can be recommended as a treatment.
This work is important because it identifies a potential mechanism-based therapeutic target for ME/CFS rooted in cellular energy dysfunction—a central feature of the disease. Rather than focusing only on symptom management, this approach suggests a possible path toward treating an underlying biological cause, which could transform how ME/CFS is managed.
This literature review does not provide clinical evidence that H₂ actually works in ME/CFS patients; it is based on extrapolation from animal studies and fatigue research in healthy populations. It does not establish that mitochondrial oxidative stress is the primary driver of ME/CFS symptoms in all patients, nor does it prove that H₂ administration is safe or practical for long-term use in humans with this condition.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.